Acquired Novo Nordisk (Ozempic)
2962 snips
Jan 22, 2024 Discover how Novo Nordisk transformed the pharmaceutical landscape with its groundbreaking diabetes and obesity treatments, Ozempic and Wegovy. The narrative uncovers the company's humble beginnings and its self-disruption akin to a tech giant's 'iPhone moment.' Dive into the intense rivalry within the insulin market and the ethical dilemmas faced in its evolution. Explore the incredible journey of GLP-1 drugs, from skepticism to success, and how they are reshaping perceptions around obesity and health management. This is a story of innovation, commitment, and the future of healthcare.
AI Snips
Chapters
Books
Transcript
Episode notes
US Pricing and Insurance
- Ozempic and Wegovy's high US prices contrast sharply with lower costs elsewhere.
- Private insurers prioritize short-term costs due to average job tenure.
Medicare and Weight Loss Drugs
- Medicare is legally prohibited from covering weight loss drugs.
- Taxpayers ultimately fund long-term health costs, creating a complex dilemma.
Insulin Market Disruption
- Insulin's profitability declined due to price caps, biosimilars, and GLP-1s.
- Novo Nordisk's shift to GLP-1s proved timely amidst these challenges.
